Skip to main content

Drug makers may have to pay 5 times more for pharma imports

By

NEW DELHI: Drug makers importing medicines may soon have to pay the government up to five times more to register their products here and get their overseas manufacturing facilities audited by the Indian regulator. The move aims to increase domestic manufacturing of medicines.  


After a meeting between the Central Drugs Standard Control Organization and industry stakeholders in August, the ministry is once again mulling a hike in fees for several regulatory submissions for foreign drug makers, said two senior health ministry officials. A similar move was suggested in December 2015 as well. 


“All stakeholders present agreed, in principle, to a hike in fees (as per the 2015 draft notification),” stated a document that ET has viewed. 

“Members also stressed (the need) to revise fees periodically after three years, instead of 15 years. The proposal for amendment in rules is under process.” Revision of fees is necessary, as rates have not been updated for more than 15 years, one of the officials said. 

“India charges much less than other countries for regulatory licenses,” the official told ET, on condition of anonymity. “Now, the Indian regulator will be at par with world regulators (in the fees that it charges). 

The health ministry is expected to soon release a draft proposing higher fees for import licenses, registration certificates for manufacturing sites overseas and CDSCO's inspections of these sites, said the official. 
For instance, the ministry is planning to increase the fees to register one manufacturing site to $10,000 from $1,500 currently. It has proposed that the fee for a registration certificate for one product be hiked to $5,000 from around $1,000 now and make it valid for three .. 


By: Asma Naqi 

Comments

Post a Comment

Thank you for your comment. Good to see that.

Popular posts from this blog

HIV remission achieved in second patient

By
A second person has experienced sustained remission from HIV-1 after ceasing treatment, reports a paper led by researchers at UCL and Imperial College London.  The case report, published in Nature and carried out with partners at the University of Cambridge and the University of Oxford, comes ten years after the first such case, known as the ‘Berlin Patient.’ Both patients were treated with stem cell transplants from donors carrying a genetic mutation that prevents expression of an HIV receptor CCR5. The subject of the new study has been in remission for 18 months after his antiretroviral therapy (ARV) was discontinued. The authors say it is too early to say with certainty that he has been cured of HIV, and will continue to monitor his condition. “At the moment the only way to treat HIV is with medications that suppress the virus, which people need to take for their entire lives, posing a particular challenge in developing countries,” said the study’s lead author, Pro...
Post a Comment
Read more

Wet Granulation Method for Tablet compression

By
B. Pharm, S.P.E.R, Jamia Hamdard, New Delhi Race With Dreams! © 2015-2016
Post a Comment
Read more